Pain, as Vertex Pharmaceuticals found out ... Supporting Vertex’s case are a pair of large clinical trials that assessed Journavx in people who underwent either a “tummy tuck” or a bunion ...

A newly approved pain medication, suzetrigine, is the first nonopioid analgesic in 25 years to receive clearance from the U.S ...

Vertex Pharmaceuticals dominates the market ... Sionna has mapped out a clinical trial strategy that could validate its different approach to the chronic respiratory disease.

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc ... providers who participated in the clinical trials and made this approval possible.

Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter ... who participated in the clinical trials and made this approval possible. With these two recent approvals for ALYFTREK and ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio ...